Univ Of Mi Hospitals & Hlth Ctrs
- Type
- Teaching hospital
- Where
- Ann Arbor, MI
- Medicare CCN
- 230046
- Received
- $67,836,312 in 4,413 records, 2024 ($26,669,623 general, $41,166,688 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 435 | $26,669,623 |
| 2024 | Research payment | 3,978 | $41,166,688 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,978 | $41,166,688 |
| Royalty or License | 34 | $20,942,789 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 93 | $2,391,590 |
| Grant | 64 | $1,497,156 |
| Space rental or facility fees (teaching hospital only) | 112 | $772,471 |
| Consulting Fee | 14 | $489,442 |
| Charitable Contribution | 14 | $362,136 |
| Long term medical supply or device loan | 9 | $138,021 |
| Education | 69 | $55,366 |
| Debt forgiveness | 26 | $20,650 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $685,096 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $518,898 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $246,042 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $236,925 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advance | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $181,869 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $113,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $91,925 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $85,385 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $66,969 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $64,256 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advance | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | OCCLUTECH US LLC | $41,196 | Grant (9 payments) | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $34,692 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Pembrolizumab for orbital and periocular cutaneous squamous cell carcinoma cSCC | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $33,210 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 mRNA-4157 | 2024 |
| 2024-12-31 | ABBVIE INC. | $33,180 | Research payment | In-kind items and services | M20-431 ABBV-CLS-484 Ph 1 2L Solid Tumors Study PTPN2i | 2024 | |
| 2024-12-31 | ABBVIE INC. | $33,095 | Research payment | In-kind items and services | DURYSTA Drug, EYE CARE | 1698-301-007 Ph3b Study (M21-488) | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $29,008 | Research payment | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $26,560 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $25,919 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $17,669 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $14,268 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $11,774 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $10,193 | Research payment | In-kind items and services | n.a. Device, THORACOSCOPY | Fetal Endoscopic Tracheal Occlusion (FETO) Trial for Congenital Diaphragmatic Hernia (CDH) | 2024 |
| 2024-12-31 | Medtronic, Inc. | $9,899 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $9,610 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,782 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,512 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $8,339 | Research payment | In-kind items and services | A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $7,982 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2024 |
| 2024-12-31 | Stryker Corporation | $7,768 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $7,296 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,682 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,049 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $4,800 | Long term medical supply or device loan | In-kind items and services | VenaCure 1470 Pro Device, ET | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,990 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2024 |
| 2024-12-31 | PFIZER INC. | $2,782 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND T | 2024 |
| 2024-12-31 | Abbott Laboratories | $2,625 | Research payment | In-kind items and services | ALINITY Device, DIAGNOSTICS | Evaluation of Traumatic Brain Injury | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $2,604 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,501 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,391 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with R | 2024 |
| 2024-12-31 | Teleflex LLC | $2,153 | Long term medical supply or device loan | In-kind items and services | WECK Device, SURGICAL | 2024 | |
| 2024-12-31 | ABBVIE INC. | $2,100 | Research payment | In-kind items and services | First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple | 2024 | |
| 2024-12-31 | PFIZER INC. | $1,697 | Research payment | Cash or cash equivalent | A PHASE 1B2 STUDY OF PF07901801 A CD47 BLOCKING AGENT WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSEDRE | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $1,662 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $1,574 | Research payment | In-kind items and services | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate | 2024 | |
| 2024-12-31 | PFIZER INC. | $1,506 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2024 |
| 2024-12-31 | Sumitomo Pharma America, Inc. | $1,200 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654 | 2024 | |
| 2024-12-31 | PFIZER INC. | $1,180 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERA | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $752 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2024 |
| 2024-12-31 | Acerta Pharma LLC | $728 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2024 |
| 2024-12-31 | ABBVIE INC. | $583 | Research payment | In-kind items and services | M16-077 Elezanumab Ph 2a POC SCI ELASCI | 2024 | |
| 2024-12-31 | Stryker Corporation | $308 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $133 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $109 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2024 |
| 2024-12-30 | PFIZER INC. | $117,000 | Research payment | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 345140EVALUATION OF SOCIAL DETERMINANT OF HEALTHSDOH | 2024 |
| 2024-12-30 | ABBVIE INC. | $41,667 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2024 | |
| 2024-12-30 | ABBVIE INC. | $34,711 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2024 |
| 2024-12-30 | ABBVIE INC. | $23,937 | Research payment | Cash or cash equivalent | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | 2024 | |
| 2024-12-30 | ABBVIE INC. | $19,282 | Research payment | Cash or cash equivalent | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | 2024 | |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $39 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $39 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-30 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-29 | MENARINI SILICON BIOSYSTEMS, INC. | $5,743 | Research payment | In-kind items and services | Deparray Device, Diagnostics | CTC-Oncoseq | 2024 |
| 2024-12-27 | PFIZER INC. | $12,494 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICL | 2024 | |
| 2024-12-27 | CSL Behring | $899 | Research payment | Cash or cash equivalent | HEMGENIX Biological, Hematology | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvo | 2024 |
| 2024-12-26 | Blueprint Medicines Corporation | $12,929 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2024 | |
| 2024-12-26 | Sebela Women's Health Inc. | $4,985 | Research payment | Cash or cash equivalent | A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU | 2024 | |
| 2024-12-26 | Galderma Laboratories, L.P. | $1,500 | Research payment | Cash or cash equivalent | A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 | 2024 | |
| 2024-12-26 | ALBIREO PHARMA, INC. | $800 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $608 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | PTC Therapeutics, Inc. | $522 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | 2024 | |
| 2024-12-26 | Edwards Lifesciences Corporation | $250 | Research payment | Cash or cash equivalent | Beating heart mitral valve repair with the HARPOON System (RESTORE) | 2024 | |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $224 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-25 | PFIZER INC. | $6,304 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERA | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $10,535 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $3,792 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $3,792 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,907 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,658 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-23 | PFIZER INC. | $18,431 | Research payment | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 345140EVALUATION OF SOCIAL DETERMINANT OF HEALTHSDOH | 2024 |
| 2024-12-23 | SANOFI US SERVICES INC. | $13,140 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | Phase 1-2 Trial Evaluating Anti-TGFB Agent (SAR439459) or Pomalidomide in Combination With Isatuximab and Dexamethasone | 2024 |
| 2024-12-23 | ABBVIE INC. | $13,137 | Research payment | Cash or cash equivalent | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Mu | 2024 | |
| 2024-12-23 | Genentech, Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-23 | PFIZER INC. | $1,600 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2024 |
| 2024-12-23 | Bausch Health US, LLC | $200 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-12-23 | CSL Behring | $33 | Research payment | In-kind items and services | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2024 | |
| 2024-12-22 | AstraZeneca Pharmaceuticals LP | $310 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | Janssen Research & Development, LLC | $48,232 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-20 | Janssen Research & Development, LLC | $22,506 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recom | 2024 | |
| 2024-12-20 | Merck Sharp & Dohme LLC | $8,751 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2024 |
| 2024-12-20 | Novo Nordisk AS | $6,877 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-20 | Ultragenyx Pharmaceutical Inc. | $4,910 | Research payment | Cash or cash equivalent | 401GSDIA02 | 2024 | |
| 2024-12-20 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | HEMGENIX Biological, Hematology | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 |
| 2024-12-20 | W. L. Gore & Associates, Inc. | $950 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2024 |
| 2024-12-20 | W. L. Gore & Associates, Inc. | $800 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an | 2024 |
| 2024-12-19 | Cook Incorporated | $208,475 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | Merck Sharp & Dohme LLC | $84,864 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Trial of KVA12123 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tum | 2024 |
| 2024-12-19 | Chiesi USA, Inc. | $45,000 | Consulting Fee | Cash or cash equivalent | CLEVIPREX Drug, CARDIOVASCULAR | 2024 | |
| 2024-12-19 | Chiesi USA, Inc. | $27,580 | Consulting Fee | Cash or cash equivalent | CLEVIPREX Drug, CARDIOVASCULAR | 2024 | |
| 2024-12-19 | Janssen Research & Development, LLC | $7,437 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $4,791 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2024 | |
| 2024-12-19 | Synthes GmbH | $4,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-19 | ALBIREO PHARMA, INC. | $2,983 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary A | 2024 |
| 2024-12-19 | Galderma Laboratories, L.P. | $1,870 | Research payment | Cash or cash equivalent | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With | 2024 | |
| 2024-12-19 | GlaxoSmithKline, LLC. | $1,025 | Research payment | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2024 |
| 2024-12-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $91,422 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Merck Sharp & Dohme LLC | $63,040 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in second line or CUE- | 2024 |
| 2024-12-18 | Bausch Health US, LLC | $45,741 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients with Non-Constipated IBS | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $32,675 | Research payment | Cash or cash equivalent | A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Part | 2024 | |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $11,583 | Research payment | Cash or cash equivalent | A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Part | 2024 | |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $9,755 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2024 | |
| 2024-12-18 | Apellis Pharmaceuticals, Inc. | $9,524 | Research payment | Cash or cash equivalent | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic At | 2024 | |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $5,435 | Research payment | Cash or cash equivalent | A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Part | 2024 | |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $4,500 | Research payment | Cash or cash equivalent | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | 2024 | |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $3,750 | Research payment | Cash or cash equivalent | A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Part | 2024 | |
| 2024-12-18 | RECORDATI_RARE_DISEASES_INC. | $3,308 | Research payment | Cash or cash equivalent | OSILODROSTAT Drug, ENDOCRINE AGENT | LCI699-RECAG-PASS-0572 | 2024 |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $3,100 | Research payment | Cash or cash equivalent | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 | |
| 2024-12-18 | VERTEX PHARMACEUTICALS INCORPORATED | $2,500 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-18 | Chiesi USA, Inc. | $2,093 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,682 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,293 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,293 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,293 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,210 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Chiesi USA, Inc. | $1,099 | Research payment | Cash or cash equivalent | MYALEPT Drug, GENERALIZED LIPODYSTROPHY | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | 2024 |
| 2024-12-18 | Tandem Diabetes Care, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $677 | Research payment | Cash or cash equivalent | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 | |
| 2024-12-18 | Abbott Laboratories | $600 | Research payment | Cash or cash equivalent | TRICLIP Device, STRUCTURAL HEART | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $495 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $200 | Research payment | Cash or cash equivalent | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | 2024 | |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $185 | Research payment | Cash or cash equivalent | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | 2024 | |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $46 | Research payment | Cash or cash equivalent | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | 2024 | |
| 2024-12-18 | Regeneron Pharmaceuticals, Inc. | $1 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2024 |
| 2024-12-17 | MENARINI SILICON BIOSYSTEMS, INC. | $125,000 | Research payment | Cash or cash equivalent | Deparray Device, Diagnostics | CTC-Oncoseq | 2024 |
| 2024-12-17 | Kite Pharma, Inc. | $3,836 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel | 2024 |
| 2024-12-17 | Medtronic, Inc. | $2,500 | Research payment | Cash or cash equivalent | VALIANT NAVION Device, Aortic Stent Grafts | DISSECT-N | 2024 |
| 2024-12-17 | PFIZER INC. | $2,030 | Research payment | Cash or cash equivalent | A PHASE 1B2 STUDY OF PF07901801 A CD47 BLOCKING AGENT WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSEDRE | 2024 | |
| 2024-12-17 | X4 Pharmaceuticals, Inc. | $1,930 | Research payment | Cash or cash equivalent | XOLREMDI Drug, Immunology | A Phase 1b/2, Open-Label, Multicenter Study of Mavorixafor in Patients With Congenital Neutropenia and Chronic Neutropen | 2024 |
| 2024-12-17 | PFIZER INC. | $1,549 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2024 |
| 2024-12-17 | ABBVIE INC. | $700 | Research payment | Cash or cash equivalent | DURYSTA Drug, EYE CARE | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | 2024 |
| 2024-12-16 | E.R. Squibb & Sons, L.L.C. | $115,000 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-12-16 | GE HEALTHCARE | $60,003 | Research payment | Cash or cash equivalent | Aisys Device, Anesthesia Delivery | EtC UM: Retrospective review of volatile anesthetic consumption, greenhouse gas emissions, and health economics of EtC v | 2024 |
| 2024-12-16 | Genentech, Inc. | $39,497 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2024 |
| 2024-12-16 | SANOFI US SERVICES INC. | $32,971 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Huma | 2024 |
| 2024-12-16 | COLOPLAST CORP | $19,350 | Research payment | Cash or cash equivalent | INTIBIA | 2024 | |
| 2024-12-16 | CSL Behring | $16,726 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2024 |
| 2024-12-16 | Bard Peripheral Vascular, Inc. | $16,311 | Research payment | Cash or cash equivalent | Lutonix AV PAS | 2024 | |
| 2024-12-16 | Janssen Research & Development, LLC | $9,592 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2024 | |
| 2024-12-16 | Medtronic, Inc. | $6,906 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-12-16 | Medtronic, Inc. | $6,906 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2024 |
| 2024-12-16 | PFIZER INC. | $6,124 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT | 2024 |
| 2024-12-16 | Ultragenyx Pharmaceutical Inc. | $3,498 | Research payment | Cash or cash equivalent | DTX401-CL401 | 2024 | |
| 2024-12-16 | Ultragenyx Pharmaceutical Inc. | $3,498 | Research payment | Cash or cash equivalent | DTX401-CL401 | 2024 | |
| 2024-12-16 | Medtronic, Inc. | $2,100 | Research payment | Cash or cash equivalent | CG FUTURE Device, Heart Valves | HVT PMCF Registry | 2024 |
| 2024-12-16 | Eisai Inc. | $750 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Stud | 2024 |
| 2024-12-16 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE | 2024 |
| 2024-12-16 | ABBVIE INC. | $150 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis | 2024 |
| 2024-12-15 | Alexion Pharmaceuticals, Inc. | $500 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-13 | Novartis Pharmaceuticals Corporation | $257,921 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patie | 2024 | |
| 2024-12-13 | Genentech, Inc. | $127,310 | Research payment | Cash or cash equivalent | Biology of Cancer Case-Control Study | 2024 | |
| 2024-12-13 | Exeltis, USA Inc. | $27,862 | Research payment | Cash or cash equivalent | SLYND Drug, CONTRACEPTIVE | LF11401 | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $25,477 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $16,480 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-13 | AtriCure, Inc. | $15,273 | Research payment | Cash or cash equivalent | ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Device, CARDIOVASCULAR | CRYOABLATION EFFECTS ON ACUTE AND CHRONIC PAIN AFTER THORACOTOMY AND THORACOSCOPY | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | $11,032 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | Phase 2 study with MRD driven adaptive strategy in treatment for newly diagnosed multiple myeloma with upfront daratum | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $9,871 | Research payment | Cash or cash equivalent | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2024 | |
| 2024-12-13 | CSL Behring | $5,212 | Research payment | Cash or cash equivalent | HEMGENIX Biological, Hematology | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | $4,999 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | Phase 2 study with MRD driven adaptive strategy in treatment for newly diagnosed multiple myeloma with upfront daratum | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $4,386 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-13 | Medtronic, Inc. | $4,324 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2024 |
| 2024-12-13 | W. L. Gore & Associates, Inc. | $4,273 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE Ascending Stent Graft in the Treatment of Isolated Lesions, Pseudoaneurysms, and Penetrating Aort | 2024 |
| 2024-12-13 | Medtronic, Inc. | $3,000 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $740 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $608 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $608 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $608 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
The latest 200 records of 4,413.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Ann Arbor, MI, county Washtenaw County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Ann Arbor, MI | County Washtenaw County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 122,036 | 369,822 | 10,077,761 |
| Population, 2020 census P1 | 123,851 | 372,258 | 10,077,331 |
| Median age B01002 | 27.7 | 35.0 | 40.2 |
| Under 18 B01001 | 12.4% | 18.2% | 21.2% |
| 65 and over B01001 | 12.9% | 15.7% | 18.6% |
| Households B11001 | 50,499 | 150,550 | 4,076,369 |
| Foreign born B05002 | 18.6% | 13.1% | 7.2% |
| Median household income B19013 | $82,212 | $89,180 | $72,875 |
| Median family income B19113 | $146,116 | $126,625 | $93,357 |
| Per capita income B19301 | $55,459 | $52,714 | $40,735 |
| Poverty rate B17001 | 23.8% | 14.2% | 13.2% |
| Unemployment rate B23025 | 3.9% | 4.6% | 5.7% |
| Civilian labor force B23025 | 65,177 | 195,907 | 5,018,449 |
| Mean commute (minutes) B08013 | 20.0 | 23.5 | 24.2 |
| Bachelor's degree or higher B15003 | 77.9% | 58.7% | 32.4% |
| Housing units B25001 | 54,399 | 159,782 | 4,622,236 |
| Owner-occupied B25003 | 45.5% | 61.6% | 73.2% |
| Renters B25003 | 54.5% | 38.4% | 26.8% |
| Median home value B25077 | $453,400 | $374,100 | $231,600 |
| Median gross rent B25064 | $1,649 | $1,463 | $1,129 |
| White, not Hispanic B03002 | 66.5% | 67.2% | 72.4% |
| Black B03002 | 6.4% | 11.3% | 13.1% |
| Hispanic or Latino B03002 | 5.5% | 5.8% | 5.9% |
| Asian B03002 | 15.6% | 9.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ann Arbor, MI.
Comments